15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs

Diagnostic Framework: CLABSI vs. CRBSI

Vascular access is indispensable in the intensive care unit for hemodynamic monitoring, vasoactive drug administration, and fluid resuscitation. However, central venous catheters (CVCs) represent the leading source of nosocomial bloodstream infections. Clinicians must understand the distinct operational and clinical definitions:

1. Central Line-Associated Bloodstream Infection (CLABSI): A public health and epidemiological surveillance definition established by the CDC National Healthcare Safety Network (NHSN). It is defined as a laboratory-confirmed bloodstream infection (LCBI) where an eligible central venous line was in place for $> 2$ calendar days (with the day of device placement counting as Day 1) on the date of the event or the day before, and the bloodstream infection cannot be attributed to an infection at another anatomical site. CLABSI is intentionally sensitive for hospital quality metrics but lacks specificity for individual bedside clinical management.
2. Catheter-Related Bloodstream Infection (CRBSI): A rigorous clinical and microbiological definition established by the Infectious Diseases Society of America (IDSA). It requires definitive microbiological proof demonstrating that the intravascular device is the specific source of the bloodstream infection.

Microbiological Diagnostic Modalities for CRBSI

When line sepsis is suspected, paired blood cultures must be drawn: one set from the catheter hub and one set from a separate peripheral venipuncture site, ensuring equal blood volumes are inoculated into culture bottles.

                 SUSPECTED CATHETER-RELATED SEPSIS
                                │
          ┌─────────────────────┴─────────────────────┐
          ▼                                           ▼
  CATHETER REMOVED                            CATHETER IN SITU
  - Maki roll-plate segment:                  - Differential Time to Positivity:
    >= 15 CFU on agar plate                     Catheter flags >= 2 hours 
  - Quantitative sonication:                    earlier than peripheral culture
    >= 10^2 CFU                               - Quantitative blood culture:
                                                Catheter-to-peripheral ratio >= 3:1

1. In Situ Diagnostic Criteria (Catheter Maintained)

• Differential Time to Positivity (DTP): Defined as the growth of the identical microorganism in culture bottles inoculated with blood drawn simultaneously from the catheter hub and a peripheral vein, where the catheter-drawn culture flags positive at least 2 hours ($\ge 2\text{ hours}$) earlier than the peripheral culture. A higher bacterial inoculum within the catheter lumen shortens the time required to reach the automated detection threshold. DTP demonstrates high sensitivity ($> 90\%$) and specificity ($> 90\%$) for central line sepsis.
• Paired Quantitative Blood Cultures: Considered the reference gold standard. A colony count of the identical organism from the catheter-drawn blood that is $\ge 3\text{-fold greater}$ (ratio $\ge 3:1$) than the colony count from the peripheral blood confirms CRBSI.

2. Catheter Removal Diagnostic Criteria

• Semiquantitative Roll-Plate Method (Maki Technique): The distal $5\text{-cm}$ segment of the catheter tip is rolled across a blood agar plate. Growth of $\ge 15\text{ CFU}$ indicates significant external catheter surface colonization and potential CRBSI when paired with matching peripheral bacteremia.
• Quantitative Sonication Method (Brun-Buisson Method): Catheter segment is flushed or sonicated in broth to dislodge intraluminal and extraluminal biofilms. Growth of $\ge 10^2\text{ CFU}$ ($100\text{ CFU}$) confirms significant catheter infection.

---

Indications for Catheter Removal vs. Salvage Protocols

Managing an infected central line requires evaluating the offending pathogen, the presence of local or metastatic complications, and the patient's vascular access anatomy.

Absolute Indications for Immediate Catheter Removal

Prompt line removal is non-negotiable under any of the following circumstances:

• High-Virulence / Biofilm Pathogens:
  • Staphylococcus aureus (both MSSA and MRSA)
  • Candida species (all species)
  • Pseudomonas aeruginosa
  • Multidrug-resistant (MDR) Gram-negative bacilli (e.g., carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia)
  • Mycobacterium species and filamentous fungi
• Clinical and Structural Complications:
  • Severe sepsis or septic shock
  • Hemodynamic instability
  • Suppurative / septic thrombophlebitis
  • Tunnel infection (erythema, induration, or tenderness extending $> 2\text{ cm}$ along the subcutaneous tract of a tunneled catheter)
  • Subcutaneous port pocket abscess
  • Documented endocarditis or metastatic seeding (e.g., septic pulmonary emboli, osteomyelitis)
  • Persistent bacteremia or fungemia continuing $> 72\text{ hours}$ despite appropriate antimicrobial therapy

Catheter Salvage Exceptions and Antibiotic Lock Therapy

Attempting catheter salvage while administering systemic therapy is acceptable only in highly selected circumstances:

• Patients with long-term cuffed tunneled catheters or totally implanted ports who have exhausted vascular access (e.g., end-stage renal disease on hemodialysis, short gut syndrome requiring total parenteral nutrition).
• Infection caused exclusively by Coagulase-Negative Staphylococci (CoNS), such as Staphylococcus epidermidis, or uncomplicated, highly susceptible enteric Gram-negative bacilli (e.g., sensitive Escherichia coli or Klebsiella pneumoniae).
• Patient is hemodynamically stable without evidence of tunnel infection, septic thrombophlebitis, or endocarditis.

Salvage Protocol:

1. Systemic targeted intravenous antimicrobial therapy for 10 to 14 days.
2. Antibiotic Lock Therapy (ALT): Instilling supraphysiological concentrations of antibiotics ($100\text{--}1000\times$ the MIC, such as vancomycin $5\text{ mg/mL}$, cefazolin $10\text{ mg/mL}$, or gentamicin $1\text{--}2\text{ mg/mL}$) combined with an anticoagulant (heparin $100\text{ units/mL}$ or sodium citrate) into each catheter lumen during inter-dialytic or dwell periods (typically $8\text{--}12\text{ hours}$ daily) for 10 to 14 days.

CLABSI Line Removal Decision Matrix

---

Staphylococcus aureus Bacteremia (SAB) Management

Staphylococcus aureus bacteremia is one of the most treacherous clinical scenarios encountered in critical care. A core clinical axiom is that S. aureus in a blood culture is NEVER a contaminant. In $> 98\%$ of cases, a single positive blood culture bottle represents true bacteremia requiring comprehensive diagnostic workup and complete therapeutic courses.

Mandatory Structured Evaluation of SAB

1. Serial Surveillance Blood Cultures: Repeat peripheral blood cultures must be obtained every 24 to 48 hours until documented clearance. The first negative blood culture establishes "Day 1" of therapy for calculating treatment duration.
2. Mandatory Echocardiography: All adult patients with SAB require echocardiographic evaluation to rule out infective endocarditis. Transesophageal echocardiography (TEE) is the definitive gold standard, demonstrating a sensitivity of $95\%$ compared to only $50\text{--}60\%$ for transthoracic echocardiography (TTE). TEE is particularly mandatory in patients with persistent bacteremia, prosthetic heart valves, intracardiac devices, hemodialysis dependence, or physical examination findings of endocarditis.
3. Identification and Eradication of Metastatic Seeding: SAB frequently metastasizes to vertebral bodies (spondylodiscitis/epidural abscess), spleen, kidneys, and lungs (septic pulmonary emboli). Back pain, persistent fever, or focal neurological deficits warrant emergent spinal MRI.

Antimicrobial Therapy: Beta-Lactam Superiority for MSSA

• Methicillin-Susceptible S. aureus (MSSA):
  • First-line therapy: Cefazolin ($2\text{ g}$ IV q8h) or an anti-staphylococcal penicillin (Nafcillin or Oxacillin $2\text{ g}$ IV q4h).
  • Critical Board Pearl: Beta-lactams are clinically superior to vancomycin for MSSA. Treating MSSA bacteremia with vancomycin results in a 2- to 3-fold higher rate of treatment failure, relapse, and staphylococcal-attributable mortality due to vancomycin's slower bactericidal killing rate and inferior tissue penetration.
• Methicillin-Resistant S. aureus (MRSA):
  • First-line therapy: Vancomycin (dosed to achieve $\text{AUC}_{24}/\text{MIC} = 400\text{--}600\text{ mg}\cdot\text{h/L}$) or Daptomycin ($8\text{--}10\text{ mg/kg}$ IV once daily).
  • When using daptomycin, high doses ($8\text{--}10\text{ mg/kg}$, higher than the FDA-approved $6\text{ mg/kg}$ label) are required for bacteremia and endocarditis to prevent emergence of resistance. Baseline and weekly serum creatine phosphokinase (CPK) levels must be monitored to detect daptomycin-induced rhabdomyolysis.

Uncomplicated vs. Complicated SAB Management Matrix

                 STAPHYLOCOCCUS AUREUS BACTEREMIA
                                │
          ┌─────────────────────┴─────────────────────┐
          ▼                                           ▼
  UNCOMPLICATED SAB                           COMPLICATED SAB
  Must meet ALL criteria:                     Meets ANY criterion:
  - Catheter removed                          - Persistent bacteremia >72h
  - Blood cultures clear within 48-72h        - Endocarditis on TEE
  - Defervescence within 72h                  - Prosthetic valve, graft, CIED
  - Normal TEE (no vegetations)               - Metastatic seeding (discitis, abscess)
  - No prosthetic material/devices            - Failure to defervesce within 72h
  - No metastatic foci                                │
          │                                           ▼
          ▼                                   TREATMENT DURATION:
  TREATMENT DURATION:                         4 to 6 WEEKS IV Therapy
  MINIMUM 14 DAYS IV Therapy
  (from first negative blood culture)

---

Catheter-Associated Urinary Tract Infections (CAUTI)

Indwelling urinary catheters are placed in $> 20\%$ of hospitalized ICU patients. CAUTI is one of the most common healthcare-associated infections, yet it represents the single most frequently misdiagnosed and overtreated condition in critical care.

Defining CAUTI vs. Asymptomatic Bacteriuria (ASB)

According to the IDSA guidelines:

• CAUTI Definition: Patients with an indwelling urinary catheter (or catheter removed within the preceding 48 hours) presenting with clinical signs and symptoms of UTI with no alternative source, accompanied by significant bacteriuria ($\ge 10^3\text{ CFU/mL}$ of one or more bacterial species in an appropriately collected urine specimen, per IDSA).
• Compatible Signs and Symptoms: Fever, rigors, altered mental status, costovertebral angle tenderness, acute flank or pelvic pain, acute hematuria, or systemic sepsis without an identifiable non-urinary source.

The Cardinal Board Rule: Asymptomatic Bacteriuria Must NOT Be Treated

• Bacterial Colonization Kinetics: Intraluminal and extraluminal biofilms form along the urinary catheter within 24 to 48 hours of placement. Catheterized patients acquire bacteriuria at a cumulative rate of $3\text{--}10\%$ per catheter day. Nearly $100\%$ of patients catheterized for $\ge 30\text{ days}$ exhibit chronic bacterial colonization.
• Pyuria and Urine Appearance: The presence of pyuria ($> 10\text{ WBC/hpf}$), cloudy urine, turbid appearance, or strong odor reflects local bladder mucosal inflammatory reaction to the foreign plastic catheter; it does not signify active tissue-invasive infection or clinical pyelonephritis.
• Clinical Harms of Overtreatment: Administering antibiotics for asymptomatic bacteriuria does not prevent subsequent CAUTI, does not lower mortality, and does not reduce bacteremia. Instead, it directly promotes Clostridioides difficile colitis, drives selective pressures for carbapenemase-resistant pathogens, and exposes patients to drug toxicity.

Management of Confirmed CAUTI

1. Catheter Removal or Exchange: If the indwelling catheter has been in place for $\ge 7\text{--}14\text{ days}$ and urinary drainage remains clinically necessary, the existing catheter must be removed and a new catheter placed prior to collecting a urine culture and initiating antimicrobial therapy. Culturing urine from an old catheter samples intraluminal biofilm rather than bladder urine.
2. Antimicrobial Duration:
   • 7 days of targeted antibiotics for patients who experience prompt clinical improvement and defervescence.
   • 10 to 14 days for patients with delayed clinical response, structural urinary tract abnormalities, or associated secondary bacteremia.